As a further significant development for ddRNAi technology, our licensee Calimmune treated their first patient in a Phase I/II trial of its HIV/AIDS therapeutic candidate, Cal 1, in July. Calimmune’s Chief Scientist, Dr Geoff Symonds, will give a brief overview of this program at our Sydney---based shareholder meeting tomorrow. His presentation will be lodged with ASX and posted on the Company’s website.
calimmune p i/ii update due tomorrow
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)